Form 8-K - Current report:
SEC Accession No. 0001628280-26-033874
Filing Date
2026-05-12
Accepted
2026-05-12 07:14:36
Documents
16
Period of Report
2026-05-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arvn-20260511.htm   iXBRL 8-K 36773
2 EX-99.1 arvn_veppanuxoutlicensex.htm EX-99.1 11743
6 arvn_veppanuxoutlicensex001.jpg GRAPHIC 231334
7 arvn_veppanuxoutlicensex002.jpg GRAPHIC 226889
8 arvn_veppanuxoutlicensex003.jpg GRAPHIC 262729
9 arvn_veppanuxoutlicensex004.jpg GRAPHIC 87019
  Complete submission text file 0001628280-26-033874.txt   1290679

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arvn-20260511.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arvn-20260511_lab.xml EX-101.LAB 23451
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arvn-20260511_pre.xml EX-101.PRE 13581
19 EXTRACTED XBRL INSTANCE DOCUMENT arvn-20260511_htm.xml XML 2816
Mailing Address 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511
Business Address 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511 203-535-1456
ARVINAS, INC. (Filer) CIK: 0001655759 (see all company filings)

EIN.: 472566120 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38672 | Film No.: 26965859
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)